Due to the complex physiological structure, microenvironment and multiple physiological
barriers, traditional anti‐cancer drugs are severely restricted from reaching the tumour site …

Methotrexate (MTX) is a folic acid antagonist, the mechanism of action is to inhibit DNA
synthesis, repair and cell proliferation by decreasing the activities of several folate …

Organic cation transporters (OCT), organic anion transporting polypeptides (OATP) and
organic anion transporters (OAT) from the solute carrier (SLC) family play an essential role …

In recent years, a dynamic development of oncology has been observed, resulting from the
increasingly frequent occurrence of neoplasms and therefore, increasing population of …

Objective: High-dose methotrexate (HDMTX) is a mainstay therapeutic agent for the
treatment of diverse hematological malignancies, and it plays a significant role in …

Background High-dose methotrexate (HD-MTX) is a potent chemotherapeutic agent used to
treat pediatric acute lymphoblastic leukemia (ALL). HD-MTX is known for cause delayed …

Purpose To develop a population pharmacokinetic (PPK) model for methotrexate (MTX)
dosage for all ages, assess the association between concentration and clearance, and …

Aim: To evaluate the association between SLCO1B1 polymorphisms and
elimination/toxicities of high-dose methotrexate (MTX). Methods: SLCO1B1 rs11045879 and …

Purpose To identify modifiable risk factors associated with prolonged clearance of
methotrexate in pediatric, adolescent, and young adult (AYA) oncology patients receiving …

Purpose To assess the risk factors associated with high-dose methotrexate (HDMTX)(≥ 1
g/m2) treatment-induced acute kidney injury (AKI). Methods Patients who received HDMTX …